Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistanceAishath Naeem, Jennifer R. Brown, Filippo Utro et al.|Blood Advances|2022Cited by 79
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLLInhye E. Ahn, Matthew S. Davids, Mohammad Omaira et al.|Blood Advances|2024Cited by 12
Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemiaJeongsook Yoon, Inhye E. Ahn, Yinglu Zhou et al.|Blood Advances|2025Cited by 12
Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLLJu-hee Yoon, Inhye E. Ahn, Yinglu Zhou et al.|Blood|2024Cited by 2
A Phase 2 Study of Acalabrutinib, Umbralisib, and Ublituximab (AU2) in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Inhye E. Ahn, Jennifer R. Brown, Yinglu Zhou et al.|Blood|2023Cited by 1